Association for Behavior Analysis International

The Association for Behavior Analysis International® (ABAI) is a nonprofit membership organization with the mission to contribute to the well-being of society by developing, enhancing, and supporting the growth and vitality of the science of behavior analysis through research, education, and practice.

Search

49th Annual Convention; Denver, CO; 2023

Event Details


Previous Page

 

B. F. Skinner Lecture Series Paper Session #145
CE Offered: BACB
Pairing with Medical Service Providers: Getting on the Same Page, Speaking the Same ABC’s
Sunday, May 28, 2023
9:00 AM–9:50 AM
Hyatt Regency, Capitol Ballroom 1-3
Area: CBM; Domain: Service Delivery
Chair: Michele R. Traub (St. Cloud State University)
CE Instructor: Takahiro Soda, M.D.
Presenting Author: TAKAHIRO SODA (University of Florida)
Abstract:

Psychopharmacological agents are prescribed in a high proportion of individuals with ASD/IDD, with several agents with formal FDA-approved indications; many are used off-label. The data-based approach that ABA providers/ RBTs who are supervised by BCBA’s is ideal for contextualizing and measuring the behaviors (e.g., self-injury) for which medications are often considered. As a result, their involvement can tremendously aid in the decision-making process about initiating, adjusting, and discontinuing medications. On the other hand, medical providers (e.g., psychiatrist) can guide the recognition of potential conditions, psychiatric and otherwise that may be leading to sudden changes in target behaviors that have been identified for behavioral intervention. Given these goals and contributions, coordinating care is beneficial and critical. Several examples of achieving such coordination of care will be presented at multiple levels of care with thoughts on how such coordination can be achieved where no ongoing relationships currently exist.

Instruction Level: Intermediate
Target Audience:

Anyone who will have patients/ clients comanaged with psychopharmacology providers, anyone that has had medical concerns for their clients

Learning Objectives: At the conclusion of this presentation, participants will be able to: (1) Identify commonly prescribed medication classes and the onset of effects as well as side effects; (2) Understand common context and information typically provided to medical providers when being asked to prescribe various interventions to address behaviors; (3) Identify suggested strategies to interface with medication prescribers to achieve a mutually beneficial relationship
 
TAKAHIRO SODA (University of Florida)
Takahiro Soda, MD, PhD is the Medical Director for the UF Health Center for Autism and Neurodevelopment and Assistant Professor of Psychiatry at the University of Florida College of Medicine. His research focuses on bridging the quality gap between the standard of care in the treatment of patients with neuropsychiatric developmental disorders and the quality of care provided in the real world and nudging clinical practice towards the use of patient-specific factors (genetics, environmental/ socioeconomic) to aid in the provision of optimal care of patients and to do so in an equitable and ethical manner. His work has been funded by the NIH, Foundation of Hope for Treatment of Mental Illness, and the UNC Quality Improvement Fellowship. He serves on the ethics as well as the autism/ intellectual developmental disorder committee of the American Academy of Child and Adolescent Psychiatry, and on the Ethics/ Policy Committee of the International Society of Psychiatric Genetics. He is a fellow of the American Psychiatric Association
 

BACK TO THE TOP

 

Back to Top
Modifed by Eddie Soh
DONATE